insulin as a measure of the glucose transport system. 7 There was no effect of clozapine on basal and insulinstimulated glucose uptake over the same range of concentrations. The same was true when glycerol release into the culture medium was measured as an index of lipolysis in the absence or presence of rising concentrations of clozapine (Table 1) .
There was no effect of clozapine on basal and insulinstimulated glucose uptake over the same range of concentrations. The same was true when glycerol release into the culture medium was measured as an index of lipolysis in the absence or presence of rising concentrations of clozapine (Table 1) .
Leptin, IL-6 and PAI-1 measurements in the culture medium were performed using commercially available ELISA kits or by radioimmunoassay. Leptin mRNA were quantitatively determined by real-time RT-PCR using light-cycler s technology. In vitro differentiated human adipocytes were exposed to rising concentrations of clozapine for 24 h. When leptin, IL-6 and PAI-1 were measured in the culture medium there was no effect of clozapine over a broad concentration range. In addition, quantitative RT-PCR of the samples did not reveal an effect of clozapine on steady-state leptin mRNA levels (Table  1) . When freshly isolated adipocytes kept in suspension culture were exposed to clozapine there was also no effect on these variables (data not shown).
Thus, the results of this experimental study clearly indicate that clozapine even at concentrations far exceeding typical plasma concentrations does not promote fat cell formation and has no effect on the metabolic and secretory functions under investigation. Therefore, it is rather unlikely that the adverse effects of clozapine on body weight and metabolism are exerted via direct action on adipose tissue, although other actions of clozapine cannot be generally excluded.
As we did not detect an effect of clozapine on leptin expression and release from fat cells, the increase in leptin concentrations observed under clozapine treatment may be a consequence of increased caloric intake or other indirect actions. 3, 4 In one of these studies clozapine was shown to induce binge eating. 3 We therefore conclude that clozapine may cause weight gain via central pathways rather than peripheral action. We agree with Leonard and Freedman 1 that the gene encoding the nicotinic acetylcholine receptor a7 subunit (CHRNA7) may play a role in schizophrenia, and that more than one gene from the chromosome 15q14 region could be involved in the pathogenesis of different forms of schizophrenia. However, our set of genetic data derived from large families does not provide evidence that CHRNA7 causes hereditary catatonic schizophrenia (SCZD10, periodic catatonia, OMIM 605419). Leonard and Freedman present a pedigree depicting a proband with three offsprings, all four affected with schizophrenia. These patients share polymorphic marker alleles centromeric of CHRNA7, thus excluding the genes distally of CHRNA7 as candidates, whereas a schizophreniarelated gene located telomeric of CHRNA7 has recently been suggested by our group. 2 Leonard and Freedman conclude that their family is more informative than our three-generation family with seven affected members, and their criticism is mainly based on the observation that affected members of the informative branch share the same 15q13-22 haplotype from the other parent (proband 0731), who has married into our extended family. Therefore, this individual could also be considered as a theoretical source for a disease mutation in the branch. However, no cases of psychiatric disorders have been reported for any members of the family of proband 0731. 3, 4 Although a second vulnerability gene may be localized in this region, cosegregation of chromosome 15 related markers and schizophrenia observed in the NIH family reported by Leonard and Freedman could also be due to chance. Sharing of common markers of any chromosomal regions divided by only three meioses is expectable for one out of four of all chromosomal loci in such a small family, resulting in a lod score of 0.6. In other words, one may expect cosegregation of markers of any chromosomal locus with a given disease coincidentally in one out of four families of this size.
An additional three-generation family of our original sample used for the genome scan (pedigree 9, depicted in Stö ber et al 4, 5 ) with three widespread branches, six affected members, and one obligate carrier has meanwhile been studied in more detail by our group. 6 This family apparently supports the locus distally of CHRNA7, since the carrier and the five affected members available for genetic studies share marker alleles between D15S1042 and D15S182, thus excluding CHRNA7 as a candidate gene also in this family. These additional linkage data derived from investigation of family 9 support our hypothesis that gene mutations causing SCZD10 are located distally of CHRNA7 in a 7.7 cM region in at least two multiplex families. Mutation analysis of candidate genes within this chromosomal region is in progress. 
